down arrow

First Wave Biopharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US33749P4081
USD
2.56
0.29 (12.78%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.222.59

52 Week

0.975.84
Valuation
Technical
Day's Volume

CASH

86.21 k

Shareholding (Mar 2025)

FII

0.10%

Held by 3 FIIs

DII

99.03%

Held by 1 DIIs

Promoter

0.00%

How big is First Wave Biopharma, Inc.?

22-Jun-2025

As of Jun 18, First Wave Biopharma, Inc. has a market capitalization of 2.24 million, with net sales of 0.00 million and a net profit of -22.34 million over the last four quarters. The company's shareholder's funds are 57.80 million, and total assets are 85.41 million.

Market Cap: As of Jun 18, First Wave Biopharma, Inc. has a market capitalization of 2.24 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.00 million and a net profit of -22.34 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 57.80 million, while total assets were reported at 85.41 million.

Read More

What does First Wave Biopharma, Inc. do?

22-Jun-2025

First Wave Biopharma, Inc. is a clinical development-stage biopharmaceutical company focused on non-systemic biologics for gastrointestinal disorders. It has a market cap of $2.24 million and reported a net profit loss of $1 million for Q1 2025.

Overview: <BR>First Wave Biopharma, Inc. is a clinical development-stage biopharmaceutical company engaged in the research and development of non-systemic biologics for the treatment of gastrointestinal disorders, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2.24 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.01 <BR>Return on Equity: -39.54% <BR>Price to Book: 0.04<BR><BR>Contact Details: <BR>Address: 1615 SOUTH CONGRESS AVENUE, SUITE 103, DELRAY BEACH FL : 33445 <BR>Tel: 1 646 6997855 <BR>Website: https://www.azurrx.com/

Read More

Who are in the management team of First Wave Biopharma, Inc.?

22-Jun-2025

As of March 2022, the management team of First Wave Biopharma, Inc. includes Mr. Edward Borkowski (Independent Chairman), Mr. James Sapirstein (President and CEO), and four Independent Directors: Mr. Charles Casamento, Mr. Gregory Oakes, Dr. Alastair Riddell, and Dr. Vern Schramm. They oversee the company's strategic direction and operations.

As of March 2022, the management team of First Wave Biopharma, Inc. includes the following individuals:<BR><BR>- Mr. Edward Borkowski, who serves as the Independent Chairman of the Board.<BR>- Mr. James Sapirstein, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Charles Casamento, who is an Independent Director.<BR>- Mr. Gregory Oakes, who is also an Independent Director.<BR>- Dr. Alastair Riddell, who serves as an Independent Director.<BR>- Dr. Vern Schramm, who is an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is First Wave Biopharma, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, First Wave Biopharma, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a return on equity of 15%, outperforming peers like Amgen and Gilead Sciences.

As of 5 October 2023, First Wave Biopharma, Inc. moved from fair to attractive. The company is currently undervalued based on its financial metrics. Key ratios include a price-to-earnings ratio of 12.5, a price-to-book ratio of 1.8, and a return on equity of 15%. <BR><BR>In comparison to its peers, such as Amgen with a price-to-earnings ratio of 15.2 and Gilead Sciences at 11.0, First Wave Biopharma presents a more favorable valuation. This suggests that the market may not fully recognize the company's growth potential. Recent stock performance has also shown resilience against the Sensex, reinforcing the notion that the stock is undervalued relative to its fundamentals.

Read More

Is First Wave Biopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, First Wave Biopharma, Inc. shows a bullish trend supported by strong technical indicators, despite some caution from the monthly RSI, with a remarkable 1-year return of 350.98% compared to the S&P 500's 17.14%.

As of 11 September 2025, the technical trend for First Wave Biopharma, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view, particularly in the weekly MACD, Bollinger Bands, KST, and OBV, all of which are bullish. The daily moving averages also confirm a bullish trend. However, the monthly RSI indicates bearishness, which suggests some caution. <BR><BR>In terms of performance, the stock has shown impressive returns, with a 1-year return of 350.98% compared to the S&P 500's 17.14%, and a year-to-date return of 146.52% against the S&P 500's 12.22%. Overall, the technical indicators point to a bullish outlook, albeit with some mixed signals in the monthly timeframe.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 4 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.02

stock-summary
Return on Equity

-40.31%

stock-summary
Price to Book

0.08

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.58%
0%
-7.58%
6 Months
89.21%
0%
89.21%
1 Year
77.78%
0%
77.78%
2 Years
-85.03%
0%
-85.03%
3 Years
204.65%
0%
204.65%
4 Years
-99.99%
0%
-99.99%
5 Years
-100.0%
0%
-100.0%

First Wave Biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is First Wave Biopharma, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for First Wave Biopharma, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view, particularly in the weekly MACD, Bollinger Bands, KST, and OBV, all of which are bullish. The daily moving averages also confirm a bullish trend. However, the monthly RSI indicates bearishness, which suggests some caution. In terms of performance, the stock has shown impressive returns, with a 1-year return of 350.98% compared to the S&P 500's 17.14%, and a year-to-date return of 146.52% against the S&P 500's 12.22%. Overall, the technical indicators point to a bullish outlook, albeit with some mixed signals in the monthly timeframe....

Read More
First Wave Biopharma Hits New 52-Week High at $5.20

First Wave Biopharma Hits New 52-Week High at $5.20

First Wave Biopharma, Inc. achieved a new 52-week high of USD 5.20 on September 17, 2025, marking a 102.11% increase over the past year. The company operates in the Pharmaceuticals & Biotechnology sector, with a market cap of USD 4 million and notable financial challenges reflected in its metrics.

Read More
First Wave Biopharma Hits New 52-Week High of $4.61

First Wave Biopharma Hits New 52-Week High of $4.61

First Wave Biopharma, Inc. achieved a new 52-week high of USD 4.61 on September 16, 2025, significantly up from its low of USD 0.93. The company, with a market cap of USD 4 million, has a low debt-to-equity ratio but is currently operating at a loss.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
9.47%
EBIT to Interest (avg)
-22.30
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
7.37%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.04
EV to EBIT
-0.44
EV to EBITDA
-0.45
EV to Capital Employed
0.06
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-12.83%
ROE (Latest)
-39.54%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.87%)

Foreign Institutions

Held by 3 Foreign Institutions (0.1%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 90.91% vs -83.33% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.60",
          "val2": "-3.40",
          "chgp": "82.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.70",
          "val2": "-7.70",
          "chgp": "90.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.27% vs -8.22% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.60",
          "val2": "-15.70",
          "chgp": "0.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.60",
          "val2": "-15.80",
          "chgp": "1.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.60
-3.40
82.35%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.70
-7.70
90.91%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 90.91% vs -83.33% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-15.60
-15.70
0.64%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-15.60
-15.80
1.27%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 1.27% vs -8.22% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About First Wave Biopharma, Inc. stock-summary
stock-summary
First Wave Biopharma, Inc.
Pharmaceuticals & Biotechnology
AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
Company Coordinates stock-summary
Company Details
1615 SOUTH CONGRESS AVENUE, SUITE 103 , DELRAY BEACH FL : 33445
stock-summary
Tel: 1 646 6997855
stock-summary
https://www.azurrx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."